Todd Wider Sells 50,000 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) Director Todd Wider sold 50,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $6.25, for a total transaction of $312,500.00. Following the completion of the transaction, the director directly owned 722,247 shares in the company, valued at $4,514,043.75. This trade represents a 6.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ASP Isotopes Price Performance

Shares of NASDAQ:ASPI opened at $5.63 on Friday. ASP Isotopes Inc. has a 12 month low of $3.92 and a 12 month high of $14.49. The firm has a market capitalization of $708.82 million, a P/E ratio of -2.71 and a beta of 3.51. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.39 and a quick ratio of 4.37. The company’s fifty day moving average price is $6.25 and its 200 day moving average price is $5.90.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The company had revenue of $8.36 million during the quarter, compared to the consensus estimate of $3.68 million.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ASP Isotopes currently has an average rating of “Hold” and a consensus price target of $13.00.

Institutional Trading of ASP Isotopes

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes during the first quarter worth approximately $30,551,000. Alyeska Investment Group L.P. increased its stake in ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after buying an additional 2,072,851 shares during the period. UBS Group AG raised its position in ASP Isotopes by 150.3% during the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock worth $12,875,000 after buying an additional 1,445,165 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of ASP Isotopes by 3,669.1% in the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock worth $12,305,000 after acquiring an additional 1,245,184 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock worth $43,451,000 after acquiring an additional 1,241,024 shares during the period. 16.80% of the stock is owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.